^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    irofulven-1 (LP-100)

    i
    Other names: LP-100, MGI 114, E 7850
    Associations

    News

    Trials
    Company:
    Allarity Therap, Eisai, Lantern Pharma
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    Associations

    News

    Trials
    6ms
    Nucleotide excision repair deficiency is a targetable therapeutic vulnerability in clear cell renal cell carcinoma. (PubMed, Sci Rep)
    Approximately 10% of ccRCC patients in the TCGA cohort showed mutational signatures consistent with ERCC2 inactivation associated NER deficiency and also substantial levels of PTGR1 expression. These patients may be responsive to irofulven, a previously abandoned anticancer agent that has minimal activity in NER-proficient cells.
    Journal
    |
    ERCC2 (Excision repair cross-complementation group 2) • PTGR1 (Prostaglandin Reductase 1) • DRD (DNA Repair Deficiency)
    |
    DDR • DRD • ERCC2 mutation • PTGR1 expression
    |
    irofulven-1 (LP-100)
    8ms
    Predicting Survival Signature of Bladder Cancer Related to Cancer-Associated Fibroblast (CAF) Constructed by Intersecting Genes in TCGA and GEO. (PubMed, Mol Biotechnol)
    Potential drugs targeted different CAF-related genes like vemurafenib, irofulven, ghiotepa, and idarubicin were found as well. We constructed a novel 9 CAF-related mRNAs prognostic model and explored the gene expression and potential functional information of related genes, which might be worthy of clinical application. In addition, potential chemotherapy drugs could provide useful insights into the potential clinical treatment of bladder cancer.
    Journal
    |
    GADD45B (Growth Arrest And DNA Damage Inducible Beta) • STMN3 (Stathmin 3)
    |
    Zelboraf (vemurafenib) • idarubicin hydrochloride • irofulven-1 (LP-100)
    10ms
    Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) (clinicaltrials.gov)
    P2, N=27, Active, not recruiting, Allarity Therapeutics | Trial completion date: May 2023 --> May 2024
    Trial completion date
    |
    docetaxel • irofulven-1 (LP-100)
    2years
    Preclinical evaluation of CAP-0121 for multidrug resistant cancers (AACR 2022)
    This response of CAP-0121 in drug resistant xenografts is observed at nontoxic doses. Synergistic action is observed when CAP-0121 is administered in combination with traditional drugs used for treating ovarian cancer, including taxanes, platinum agents, and PARP inhibitors.
    Preclinical
    |
    ABCB1 (ATP Binding Cassette Subfamily B Member 1)
    |
    CAP-0121 • irofulven-1 (LP-100)
    2years
    Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) (clinicaltrials.gov)
    P2 | N=27 | Active, not recruiting | Sponsor: Allarity Therapeutics | Trial completion date: Oct 2021 --> Mar 2022
    Trial completion date
    |
    docetaxel • irofulven-1 (LP-100) • prednisolone
    over5years
    Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) (clinicaltrials.gov)
    P2; N=27; Recruiting; Sponsor: Oncology Venture
    New P2 trial
    |
    docetaxel • irofulven-1 (LP-100) • prednisolone